Latest From Biotech Now

USDA Deregulates Non-Browning Apples

Arctic Apple

Today, the U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection announced its decision to deregulate two varieties of Okanagan Specialty Fruits Inc. (OSF)’s specialty non-browning apples. APHIS is taking this action based on a final plant pest risk assessment (PPRA) that finds the GE apples are unlikely to pose a plant pest risk to agriculture and other plants in the United States. APHIS also completed an environmental assessment (EA) to comply with the Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Can Biotech Opponents Quash Scientific Facts?

Keith Kloor

Why are GMO opponents so worried about scientists who talk about biotechnology? Are they worried that the public will actually learn that GMOs aren’t scary and that they actually help make agriculture more sustainable and help keep food costs low? Are opponent groups scared of scientific facts? Science writer Keith Kloor explains in an article posted on the Science website that a dozen public sector scientists working in the field of biotechnology were hit with Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Achieving Food Security by 2050

“As the world population surpasses 9 billion people as estimated in 2050, increased demand for beef will be driven by the estimated 3 billion people expected to join the middle class who will be able to afford to add meat, milk and eggs to their diets,” Elanco, a global animal health company, claimed in a recent release. Agrimarketing covered Elanco’s statement on how farming innovations have allowed the beef industry to freeze carbon footprint and save Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , ,

Deal Structures: More Options for Companies

CEO2013_115x75_Thumbnail copy

By most measures, 2014 was a great year for the biotechnology industry. Venture capital deal values, , licensing values and volume were all up, as were big pharma M&A deals and asset swaps. What do these trends mean for dealmakers in 2015? Answering that question was the task of a panel at the 2015 BIO CEO & Investor Conference, Emerging Trends in Deal Structures. Moderated by Fenwick and West’s Effie Toshav, the panel included: Bruce Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,

Fireside Chats with Five CEOs Featured at Day Two of the BIO CEO & Investor Conference

DSC_9222

Fireside Chat with John F. Milligan, PhD, President & COO, Gilead Sciences The first fireside chat of the BIO CEO and Investor Conference featured John F. Milligan, Ph.D. President & COO of Gilead Sciences.  In a session moderated by Barclays analyst Geoff Meacham, Dr. Milligan was optimistic that sales of Gilead’s Hepatitis C treatments would see expanded sales volumes as more providers become comfortable with the regimens and treating HCV patients, according to Milligan. He Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,